Treatment
individualized anti-tumor new antigen iNeo-Vac-R01 clinical trials
We’re tracking 6 recruiting studies that include individualized anti-tumor new antigen iNeo-Vac-R01, each written for real people, not researchers, below.
Recruiting studies
- NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07368803RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for bile duct cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
Hangzhou, ZhejiangAges 18–75 - NCT06019702RecruitingPhase 1
Personalized mRNA vaccine for advanced digestive cancers
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
Hangzhou, ZhejiangAges 18–75 - NCT06026774RecruitingPhase 1
Personalized mRNA Vaccine After Digestive Cancer Surgery
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
Hangzhou, ZhejiangAges 18–75 - NCT06026800RecruitingPhase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Hangzhou, ZhejiangAges 18–75
What individualized anti-tumor new antigen iNeo-Vac-R01 is being studied for
Conditions with recruiting individualized anti-tumor new antigen iNeo-Vac-R01 studies.
Common questions
- Are there clinical trials studying individualized anti-tumor new antigen iNeo-Vac-R01?
- Yes. Clin2 currently lists 6 recruiting studies that include individualized anti-tumor new antigen iNeo-Vac-R01, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a individualized anti-tumor new antigen iNeo-Vac-R01 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is individualized anti-tumor new antigen iNeo-Vac-R01 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether individualized anti-tumor new antigen iNeo-Vac-R01 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.